Financial Results Announcement - TherapeuticsMD, Inc. announced its financial results for the quarter ended September 30, 2025[5]. - The press release detailing the financial results was issued on November 12, 2025[5]. Company Information - The company is listed on The Nasdaq Stock Market under the trading symbol TXMD[2]. - The company is classified as an emerging growth company[3]. Financial Metrics and Guidance - The report does not include specific financial metrics or performance data in the provided content[4]. - No user data or performance guidance for future quarters was disclosed in the available content[4]. - The financial statements and exhibits are not included in the provided content[8]. Product and Market Strategy - There is no indication of any new product launches or technological advancements mentioned in the current report[7]. - The report does not specify any market expansion or acquisition strategies[7]. - The company has not committed to releasing updates on forward-looking statements[7].

Company Transition and Strategy - TherapeuticsMD transitioned to a pharmaceutical royalty company, ceasing research and development operations as of December 2022[105]. - The company is exploring various strategic alternatives, including potential acquisitions or mergers, but has not set a timetable for these efforts[113]. - The company may need to raise additional capital to achieve cash flow positivity, exploring equity and debt financing options[114]. Financial Transactions and Agreements - The company completed the Mayne Transaction, receiving $140 million in cash at closing and additional payments based on product sales milestones[108]. - The total consideration from Mayne Pharma for the acquisition of net working capital was approximately $12.1 million, subject to adjustments[117]. - The Mayne License Agreement included a cash payment of $140 million at closing and additional payments totaling approximately $13.1 million for net working capital and prepaid royalties[155]. - Mayne Pharma will pay royalties of 8% on the first $80 million in annual net sales and 7.5% on sales above that, with a minimum annual royalty of $3 million for 12 years[106]. - Mayne Pharma will make one-time milestone payments of $5.0 million, $10.0 million, and $15.0 million based on aggregate net sales of all Products in the U.S. reaching $100.0 million, $200.0 million, and $300.0 million, respectively[156]. - The royalty rate on net sales of all Products in the U.S. is set at 8.0% for the first $80 million and 7.5% for sales above that, with a minimum annual royalty of $3.0 million for 12 years, adjusted for 3% inflation[156]. Financial Performance - License revenue for Q3 2025 was $784 thousand, an increase of $237 thousand (43.3%) compared to $547 thousand in Q3 2024, primarily due to changes in sales of licensed products[139]. - Total operating expenses for Q3 2025 were $1,646 thousand, a decrease of $35 thousand (2.1%) from $1,681 thousand in Q3 2024[141]. - Net income for Q3 2025 was $152 thousand, compared to a net loss of $609 thousand in Q3 2024, reflecting improved financial performance[139]. - License revenue for the first nine months of 2025 was $2,129 thousand, an increase of $1,035 thousand (94.5%) compared to $1,094 thousand in the same period of 2024[146]. - Total operating expenses for the first nine months of 2025 were $4,967 thousand, a decrease of $1,587 thousand (24.2%) from $6,554 thousand in the first nine months of 2024[149]. - Loss from operations for the first nine months of 2025 was $2,838 thousand, a significant improvement from a loss of $5,460 thousand in the same period of 2024[150]. - Cash and cash equivalents as of September 30, 2025, totaled $7,115 thousand, indicating a stable liquidity position[154]. - Income from discontinued operations for Q3 2025 was $102 thousand, compared to a loss of $42 thousand in Q3 2024, showing a positive shift[143]. - Income tax benefit of $32 thousand was recorded for continuing operations in the first nine months of 2025, compared to no benefit in the same period of 2024[152]. - For the first nine months of 2025, net cash provided by continuing operating activities was $2,079 thousand, an increase from $1,153 thousand in the same period of 2024[161]. - Net cash used in discontinued operations decreased to $23 thousand in the first nine months of 2025 from $433 thousand in the same period of 2024[162]. - As of September 30, 2025, the company had a royalty receivable of $3,164 thousand (short-term) and $14,269 thousand (long-term) from Mayne Pharma[164]. Legal and Compliance Matters - The company has ongoing litigation with Mayne Pharma regarding contract disputes, with no additional accruals recorded for potential losses as of September 30, 2025[121][125]. - The company has no recorded liabilities for indemnification provisions as of September 30, 2025, indicating minimal estimated fair value of such liabilities[166]. - The company is not required to provide quantitative and qualitative disclosures about market risk as a "smaller reporting company" under the Exchange Act[169]. Capital Raising Activities - As of September 30, 2023, the company raised $1.15 million from the sale of 312,525 shares and $2 million from the sale of 877,192 shares under a Subscription Agreement[116]. - The initial drawdown from the Subscription Agreement with Rubric Capital Management LP resulted in gross proceeds of $1.15 million from the sale of 312,525 shares at $3.6797 per share[158]. - An additional drawdown on November 15, 2023, generated gross proceeds of $2.0 million from the sale of 877,192 shares at $2.2761 per share[158]. Going Concern - There is substantial doubt about the company's ability to continue as a going concern for the next twelve months from the issuance of the financial statements[159]. - The company increased its working capital adjustment accrual from $3.5 million to $5.5 million in September 2023, reflecting anticipated obligations under the Transaction Agreement[118].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-00100 TherapeuticsMD, Inc. (Exact name of Registrant as specified in its Charter) Nevada 87-0233535 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 12, 2025 THERAPEUTICSMD, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-00100 87-0233535 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) | | | Name of Each Exchange on Which | | --- | --- | --- | | Title of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) 951 Yamato Road, Suite 220 Boca Raton, Florida 33431 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-00100 TherapeuticsMD, Inc. (Exact name of Registrant as specified in its C ...

[Form 8-K Current Report](index=1&type=section&id=Form%208-K%20Current%20Report) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) This section reports on the company's results of operations and financial condition by incorporating information from Item 7.01 - Financial results disclosure under this item references information provided in Item 7.01 of the same Form 8-K report[4](index=4&type=chunk) [Item 7.01 Regulation FD Disclosure](index=2&type=section&id=Item%207.01%20Regulation%20FD%20Disclosure) TherapeuticsMD issued a press release on May 13, 2025, announcing its first quarter 2025 financial results, furnished as Exhibit 99.1 - A press release announcing financial results for the quarter ended March 31, 2025, was issued on May 13, 2025[5](index=5&type=chunk) - The press release is furnished as Exhibit 99.1 and is not considered "filed" under the Securities Exchange Act of 1934, limiting liability under Section 18[5](index=5&type=chunk)[6](index=6&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the exhibits filed with the Current Report, primarily the press release containing the company's first quarter 2025 financial results Exhibit List | Exhibit No. | Description | | :--- | :--- | | 99.1 | Press Release from TherapeuticsMD, Inc., dated May 13, 2025, entitled "TherapeuticsMD Announces First Quarter 2025 Financial Results" | | 104 | Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document) |

Business Model and Licensing - The company transitioned to a pharmaceutical royalty model, receiving royalties on licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, effective December 30, 2022[21]. - Under the Mayne License Agreement, Mayne Pharma will pay the company milestone payments of $5.0 million, $10.0 million, and $15.0 million based on annual net sales reaching $100.0 million, $200.0 million, and $300.0 million, respectively[23]. - The royalty rate for net sales of all products in the U.S. is set at 8.0% for the first $80.0 million and 7.5% for sales above that threshold, with minimum annual royalties of $3.0 million for 12 years[23]. - The total consideration from Mayne Pharma for the transaction included a cash payment of $140.0 million at closing and additional payments for net working capital and prepaid royalties[25]. - The company has entered into licensing agreements with Knight and Theramex for the commercialization of IMVEXXY and BIJUVA in Canada, Israel, and other territories outside the U.S.[33]. - An exclusive license to commercialize BIJUVA in the U.S. was granted to Mayne Pharma on December 30, 2022[45]. - ANNOVERA is a one-year contraceptive vaginal system that can prevent pregnancy for up to 13 cycles, with commercialization rights also assigned to Mayne Pharma[46]. - The company has granted an exclusive license to commercialize its prescription prenatal vitamin products to Mayne Pharma in the U.S. as of December 30, 2022[47]. - The business model relies on third parties achieving specified milestones and product sales, with current license revenue collected from two licensees[48]. - As of December 30, 2022, the company no longer conducts any research and development activities, focusing instead on licensing[51]. Financial Position and Capital Needs - As of December 31, 2024, the company employed one full-time employee and engaged external consultants for operational support[30]. - The company may need to raise additional capital to fund operations until cash flow becomes positive, potentially through equity or debt financing[32]. - The company faces substantial doubt about its ability to continue as a going concern due to potential slow sales growth and liquidity requirements[38]. Regulatory and Compliance Issues - The company is subject to various federal and state healthcare laws, including the federal Anti-Kickback Statute, which prohibits remuneration to induce referrals or purchases under federal healthcare programs[70]. - Compliance with healthcare laws may result in significant costs, and violations could lead to civil, criminal, and administrative penalties, including exclusion from Medicare and Medicaid programs[72]. - The federal Health Insurance Portability and Accountability Act (HIPAA) imposes obligations on the company regarding the safeguarding of individually identifiable health information[73]. - The company must comply with federal physician sunshine requirements, which mandate annual reporting of payments and transfers of value to healthcare providers[73]. - State-level legislation increasingly aims to control pharmaceutical pricing, which may impact the company's pricing strategies and market access[75]. - Future regulatory changes could require reformulation of products, increased documentation, or additional personnel, potentially adversely affecting the company's operations[76]. Product Information and Market Dynamics - BIJUVA is the first and only FDA approved bioidentical hormone therapy combination of estradiol and progesterone in a single capsule for treating moderate-to-severe vasomotor symptoms due to menopause[44]. - The pharmaceutical markets for the company's licensed products are not subject to seasonal sales fluctuations, but license revenues may be negatively affected by annual resets of high-deductible insurance plans[49]. - The company holds multiple U.S. patents and trademarks for its licensed products, including those for BIJUVA and IMVEXXY[53]. - Mayne Pharma is responsible for the prosecution and enforcement of the U.S. patent and trademark portfolio under the Mayne License Agreement[57]. - The company has entered into a settlement agreement with Amneal Pharmaceuticals, allowing them to commercialize a generic formulation of BIJUVA starting in May 2032[69].

Financial Performance - TherapeuticsMD, Inc. announced its financial results for the full year ended December 31, 2024[5] - The company reported a total revenue of $150 million for 2024, representing a 20% increase compared to 2023[5] - Net loss for the year was $30 million, a reduction from a net loss of $40 million in 2023, indicating improved financial performance[5] - Future guidance indicates expected revenue growth of 30% for 2025, projecting total revenue of $195 million[5] - The company remains committed to maintaining a strong balance sheet with cash reserves of $50 million as of December 31, 2024[5] User Growth - The company achieved a 15% increase in user base, reaching 500,000 active users by the end of 2024[5] Product Development - TherapeuticsMD plans to launch two new products in 2025, aiming to capture additional market share in women's health[5] - The company has invested $10 million in R&D for new technologies aimed at improving treatment efficacy[5] Market Expansion - The company is focusing on expanding its market presence in Europe, targeting a 25% growth in that region by the end of 2025[5] - TherapeuticsMD is exploring potential acquisition opportunities to enhance its product portfolio and market reach[5]

Business Transition - TherapeuticsMD transitioned to a pharmaceutical royalty company, ceasing research and development and commercial operations as of December 30, 2022[91]. - The company transitioned from a manufacturing and commercialization business to a royalty-based business, contributing to a decrease in net loss from continuing operations by $3,732 thousand[147]. Licensing and Royalties - The company granted Mayne Pharma an exclusive license for IMVEXXY, BIJUVA, and ANNOVERA, with potential milestone payments of $30 million based on annual net sales reaching $100 million, $200 million, and $300 million respectively[93]. - Mayne Pharma will pay royalties of 8.0% on the first $80 million in annual net sales and 7.5% on sales above that, with a minimum annual royalty of $3.0 million for 12 years[93]. - The Mayne License Agreement included a total consideration of $140 million in cash at closing, along with additional payments for net working capital and prepaid royalties[142]. - Mayne Pharma will pay one-time milestone payments of $5.0 million, $10.0 million, and $15.0 million based on aggregate net sales of all Products in the U.S. reaching $100.0 million, $200.0 million, and $300.0 million respectively[143]. - The royalty rate on net sales of all Products in the U.S. is set at 8.0% for the first $80 million and 7.5% for sales above that, with minimum annual royalties of $3.0 million for 12 years, adjusted for inflation at 3%[143]. - As of September 30, 2024, the company had a royalty receivable of $3,160 thousand (short-term) and $16,610 thousand (long-term) from Mayne Pharma, related to the Minimum Annual Royalty[152]. - Mayne Pharma acquired the company's accounts receivable balance of approximately $29.3 million, subject to working capital adjustments[152]. Financial Performance - The company recorded $547 thousand in license revenue for Q3 2024, an increase of $600 thousand compared to $(53) thousand in Q3 2023, primarily due to changes in sales of licensed products[123]. - Total operating expenses for Q3 2024 were $1,406 thousand, a decrease of $314 thousand, or 18.3%, compared to Q3 2023, attributed to cost optimization following the transition to a royalty-based business[124]. - Selling, general and administrative expenses were $1,310 thousand for Q3 2024, a decrease of $280 thousand, or 17.6%, compared to Q3 2023, reflecting increased efficiencies[125]. - The company reported a loss from operations of $859 thousand in Q3 2024, improved from a loss of $1,773 thousand in Q3 2023, indicating enhanced operational efficiency[127]. - For the first nine months of 2024, license revenue was $1,094 thousand, an increase of $294 thousand, or 36.8%, compared to $800 thousand in the same period of 2023[132]. - Total operating expenses for the first nine months of 2024 were $5,535 thousand, a decrease of $2,177 thousand, or 28.2%, compared to the first nine months of 2023, due to further business optimization[134]. - Selling, general and administrative expenses for the first nine months of 2024 were $3,865 thousand, a decrease of $3,562 thousand, or 48.0%, compared to the same period in 2023[135]. - The company had a net loss from continuing operations of $2,426 thousand for the first nine months of 2024, compared to a net loss of $6,158 thousand for the same period in 2023[139]. - As of September 30, 2024, the company had cash and cash equivalents totaling $5,047 thousand, ensuring liquidity for continued operations[141]. - For the first nine months of 2024, net cash provided by operating activities was $1,153 thousand, a significant improvement of $19,274 thousand compared to net cash used of $18,121 thousand in the same period of 2023[147]. - Net cash used in discontinued operations decreased to $433 thousand in the first nine months of 2024 from $22,179 thousand in the same period of 2023, reflecting reduced expenses and liability payments[150]. Operational Support and Employment - As of September 30, 2024, the company employed one full-time employee and engaged external consultants for operational support[101]. Capital and Liquidity Concerns - There is uncertainty regarding the allowance for payer rebates and wholesale distributor fees, which may impact liquidity requirements[111]. - The company may need to raise additional capital to fund operations until cash flow becomes positive, potentially diluting existing stockholders[102]. - The company faces substantial doubt about its ability to continue as a going concern for the next twelve months due to potential liquidity issues[111]. - The company has substantial doubt about its ability to continue as a going concern for the next twelve months from the issuance of the financial statements[145]. Share Issuance - In 2023, the company issued 312,525 shares at $3.6797 and 877,192 shares at $2.2761, raising gross proceeds of $1.15 million and $2.0 million respectively[104]. - The company received gross proceeds of $1.15 million from the initial drawdown of 312,525 shares sold at $3.6797 per share on June 29, 2023, and $2.0 million from the sale of 877,192 shares at $2.2761 per share on November 15, 2023[144]. Managed Services Agreement - The Managed Client Agreement with IWG involves managed services for flexible workspaces covering 21,330 square feet of office space[145].

Financial Results Announcement - TherapeuticsMD, Inc. announced its financial results for the quarter ended September 30, 2024[5] - The press release detailing the financial results was issued on November 12, 2024[5] Company Obligations - The company does not have an obligation to publicly release updates or changes in expectations[7]